- Home
- FLR vs ROIV Comparison
FLR vs ROIV Comparison
Compare FLR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLR
- ROIV
- Stock Information
- Founded
- FLR 1912
- ROIV 2014
- Country
- FLR United States
- ROIV United Kingdom
- Employees
- FLR N/A
- ROIV N/A
- Industry
- FLR Military/Government/Technical
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- FLR Industrials
- ROIV Health Care
- Exchange
- FLR Nasdaq
- ROIV Nasdaq
- Market Cap
- FLR 7.2B
- ROIV 8.6B
- IPO Year
- FLR N/A
- ROIV N/A
- Fundamental
- Price
- FLR $43.03
- ROIV $16.14
- Analyst Decision
- FLR Buy
- ROIV Strong Buy
- Analyst Count
- FLR 7
- ROIV 8
- Target Price
- FLR $50.57
- ROIV $19.94
- AVG Volume (30 Days)
- FLR 3.3M
- ROIV 9.5M
- Earning Date
- FLR 11-07-2025
- ROIV 11-11-2025
- Dividend Yield
- FLR N/A
- ROIV N/A
- EPS Growth
- FLR 970.51
- ROIV N/A
- EPS
- FLR 24.07
- ROIV N/A
- Revenue
- FLR $16,313,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- FLR $3.29
- ROIV N/A
- Revenue Next Year
- FLR $4.33
- ROIV $248.22
- P/E Ratio
- FLR $1.78
- ROIV N/A
- Revenue Growth
- FLR 3.61
- ROIV N/A
- 52 Week Low
- FLR $29.20
- ROIV $8.73
- 52 Week High
- FLR $60.10
- ROIV $16.79
- Technical
- Relative Strength Index (RSI)
- FLR 50.07
- ROIV 77.88
- Support Level
- FLR $42.53
- ROIV $14.86
- Resistance Level
- FLR $44.62
- ROIV $16.79
- Average True Range (ATR)
- FLR 1.54
- ROIV 0.47
- MACD
- FLR 0.21
- ROIV 0.05
- Stochastic Oscillator
- FLR 49.80
- ROIV 72.27
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.